The tyrosine kinase Src is frequently activated in advanced human prostate carcinomas and its activation correlates with tyrosine phosphorylation of the RNAbinding protein Sam68. Herein, we have investigated the expression and function of Sam68 in human prostate cancer cells. Analysis of specimens obtained from 20 patients revealed that Sam68 is upregulated at the protein level in 35% of the samples. Real-time polymerase chain reaction confirmed the results at the mRNA level in most patients. Downregulation of Sam68 by RNAi in LNCaP prostate cancer cells delayed cell cycle progression and reduced the proliferation rate. Moreover, depletion of Sam68 sensitized cells to apoptosis induced by DNAdamaging agents. Similarly, stable cell lines expressing a truncated GFP-Sam68 GSG protein displayed reduced growth rates and higher sensitivity to cisplatin-induced apoptosis. Microarray analyses revealed that a subset of genes involved in proliferation and apoptosis were altered when Sam68 was knocked down in LNCaP cells. Our results indicate that Sam68 expression supports prostate cancer cells proliferation and survival to cytotoxic agents.
Introduction
Prostate carcinoma (PCa) originates as an androgendependent hyper-proliferation of the epithelial cells of the gland and it evolves in an androgen-independent, highly aggressive cancer for which no cure is available yet (Feldman and Feldman, 2001) . As androgenrefractoriness is associated with poor prognosis, it is of primary importance to identify the molecular pathways that can be targeted by therapies alternative to androgen-depletion. A predominant role in the development of androgen-refractoriness is played by the upregulation of signal transduction pathways that allow prostate cancer cells to autonomously produce their own requirements of growth factors and nutrients (Grossmann et al., 2001) . In many cases, these autocrine loops trigger the activation of tyrosine kinase pathways. In this regard, it was shown that the tyrosine kinase Src is required for proliferation and migration of prostate cancer cells (Migliaccio et al., 2000; Lee et al., 2001) and that inhibition of Src blocks their adhesion to the extracellular matrix and invasiveness (Nam et al., 2005) .
Src is the prototype of a class of tyrosine kinases that have been intensively studied due to their impact on cell tranformation and tumour development (Irby and Yeatman, 2000) . The activity of Src-related tyrosine kinases is increased in a multitude of primary tumours and metastatic lesions and Src-specific inhibitors may have a therapeutic application in inhibiting tumour progression and/or metastasis (Nam et al., 2005) . In line with the role of Src in PCa, the tumour suppressor DOC2/DAB2, an endogenous Src inhibitory protein, is frequently downregulated in this cancer (Zhou et al., 2003) , whereas an activator of Src, the truncated c-Kit protein tr-Kit, is aberrantly expressed in prostate tumours at advanced stage of the disease. Activation of Src in these PCas correlated with tyrosine phosphorylation of Sam68 (Src substrate in Mitosis, 68 kDa) (Paronetto et al., 2004) , an RNA-binding protein that acts as a post-transcriptional regulator of gene expression (Lukong and Richard, 2003) .
Sam68 belongs to the signal transduction and activation of RNA metabolism (STAR) family of RNA-binding proteins, which appear to link signal transduction pathways with the regulation of RNA metabolism (Lukong and Richard, 2003) . They are characterized by a GSG (Gpr33-Sam68-GLD-1) domain, which is required for RNA binding and homodimerization, flanked by regions involved in protein-protein interactions and post-translational modifications, which affect the affinity and specificity of RNA binding. In particular, Sam68 interacts with the SH2 and SH3 domains of several signalling proteins acting as a scaffold molecule in response to different stimuli (Richard et al., 1995; Paronetto et al., 2003) . Physical interaction with Src-related kinases and tyrosine phosphorylation of Sam68 (Lukong and Richard, 2003) cause a decreased affinity for RNA. Moreover, it was shown that Sam68 is phosphorylated by the Erk1/2 mitogen-activated protein kinases (MAPK) in response to external cues. As this modification affects alternative splicing of the CD44 receptor pre-mRNA (Matter et al., 2002) , Sam68 may link growth factors signalling to posttranscriptional modulation of gene expression. The intracellular localization of Sam68 is also regulated by post-translational modifications like methylation (Cote et al., 2003) , tyrosine phosphorylation (Paronetto et al., 2003; Lukong et al., 2005) and by its ability to bind to polysomes (Paronetto et al., 2006) . Although a direct role in translation has not been demonstrated yet, several observations indicate that Sam68 can substitute for the HIV protein Rev and mediate nuclear export and cytoplasmic utilization of viral mRNA (Reddy et al., 1999; Soros et al., 2001; Coyle et al., 2003) . Interestingly, a physiological dominant-negative isoform of Sam68, with a deletion in the RNA-binding domain, is expressed by normal cells when they reach confluence and causes cell cycle arrest (Barlat et al., 1997) , suggesting that Sam68 function is beneficial to cell proliferation.
Recent high-throughput screens have demonstrated that changes in alternative splicing can be more informative than changes in global transcription to classify PCa phenotypes Zhang et al., 2006) . However, no specific information is available on the aberrant expression or regulation of RNA-binding proteins and splicing factors in prostate cancer cells. Herein, the expression and function of Sam68 in prostate cancer cells was investigated. We report that Sam68 protein is frequently upregulated in the epithelial cells of human PCas and that this protein supports prostate cancer cell proliferation and survival.
Results

Sam68 is upregulated in human prostate carcinomas
The expression of Sam68 was analysed in 20 patients with different stages of PCa lesions (Table 1) . Western blot analysis performed on extracts obtained from the neoplastic tissue and from the contralateral part of the gland, indicated that Sam68 protein was upregulated in 35% of the neoplastic tissues tested (Figure 1a ; Table 1 ). Real-time PCR from total RNA obtained from the same tissues confirmed the upregulation of Sam68 at the mRNA level in most of the patients examined ( Figure 1b and Table 1 ). The clinical profile of the patients examined and a summary of the results obtained are described in Table 1 .
Neoplastic lesions often correlate with an inflammatory response and with recruitment of blood cells in the prostate gland (Palapattu et al., 2005) . To determine whether upregulation of Sam68 occurred in the prostate epithelial cells or in the invading inflammatory cells, immunohistochemistry analysis was performed on the subset of samples displaying elevated levels of Sam68. As illustrated in Figure 2a -c, Sam68 was expressed at moderate levels in approximately half of the epithelial cells of normal prostate glands. By contrast, all epithelial cells of neoplastic glands were strongly positive to Sam68 and in some samples these cells had already invaded the surrounding stroma (Figure 2d-f) . This result suggests that elevated expression of Sam68 correlates with the neoplastic phenotype of prostate epithelial cells. Sam68 was expressed by cells both in G1 phase and in mitosis, as shown by staining Figure 3a ). Cell number counts and MTS assays indicated that downregulation of Sam68 causes a decrease in the proliferation rate of LNCaP cells (Figure 3b ). Similar results were also obtained with the si1 Sam68 RNA (data not shown), indicating that the effect is specific for Sam68. BrdU-labeling showed that reduction of Sam68 obtained with both siRNAs resulted in a slightly decreased number of cells in S phase ( Figure 3c ). These data indicate that high levels of Sam68 are required for optimal proliferation of LNCaP cells. To determine if cell cycle progression was delayed by depletion of Sam68, transfected LNCaP were treated with mimosine or thymidine, to induce a block in G1/S or with nocodazole to induce a block in G2/M. Scrambled-transfected LNCaP ( Figure 3d ) were prevalently in G1 (73% of cells) with only a small fraction of cells in G2/M phase (12%). Treatment with mimosine or thymidine caused a further accumulation of cells in G1/ S phase and mimosine caused also an increase in the levels of cyclin D1, a marker of the G1/S transition ( Figure 3d ). Interestingly, we observed that depletion of Sam68 in unsynchronized LNCaP cells augmented the G1 population (77% of cells) and decreased the G2/M (8%), with a concomitant increase in cyclin D1 levels and a decrease in cyclin B1. Mimosine and thymidine did not alter this pattern, but G2/M (21% of cells versus 33% in control transfected cells) and cyclin B1 accumulation induced by nocodozole were less evident. As LNCaP cells are prevalently in G1 in the unsynchronized population, these results indicate that depletion of Sam68 delays entry into G2/M in the 16 h of the treatment.
Downregulation of Sam68 sensitizes LNCaP cells to apoptosis
To test whether Sam68 plays a role in LNCaP cell survival, we analysed apoptosis induced by the chemotherapeutic agents cisplatin and etoposide. Downregulation of Sam68 did not affect activation of caspase 3 or PARP-1 cleavage ( A GFP-Sam68 GSG chimeric protein interferes with LNCaP proliferation and survival Sam68 function is modulated by post-translational modifications that occur on the regions flanking the GSG domain (Chen et al., 1999; Lukong and Richard, 2003) . In an attempt to interfere with Sam68 function in vivo, we established LNCaP cell lines stably transfected with a GFP-Sam68 GSG chimeric protein.
Although mainly cytoplasmic (Figure 5a ), a fraction of GFP-Sam68 GSG was nuclear and interacted with the endogenous Sam68, as demonstrated by co-immunoprecipitation experiments from nuclear extracts ( Figure 5b ). To test whether this interaction interferes with Sam68 function, we performed an in vivo splicing assay using the CD44 v5 minigene (Matter et al., 2002) . Indeed, v5 exon inclusion induced by Sam68 in the CD44-positive PC3 prostate cancer cells was partially inhibited by the truncated myc-Sam68 GSG protein (Figure 5c ). Interestingly, GFP-Sam68 was constitutively active in the PC3 prostate cancer cells and did not require stimulation of the MAPK pathway by either EGF or TPA (Supplementary Figure 1 ). In agreement with its interfering role, the two stable clones expressing GFP-Sam68 GSG (GFP-GSG3 and GFP-GSG5) displayed reduced proliferation rate ( Figure 5e ) and were more sensitive to treatment with cisplatin ( Figure 5d ). Hence, the effects produced by expression of GFP-Sam68 GSG resemble those obtained by downregulation of Sam68 by RNAi and indicate that interference with Sam68 function impairs LNCaP cell proliferation and survival to DNAdamaging agents.
Gene expression profile of Sam68-silenced LNCaP cells Next, we hybridized RNAs obtained from scrambled siRNA-or siSam68-transfected LNCaP cells onto microarray chips containing a subset of 263 genes with known relevance to prostate cancer cells proliferation and apoptosis (Figure 6a and b). Although silencing of Sam68 did not cause large-spectrum changes in gene expression, selected genes were either upregulated or downregulated between 2-and 10-fold (Table 2) . We found that depletion of Sam68 caused the downregulation of genes reported to protect from apoptosis, such as Bcl2L1 (confirmed also at the protein level, Figure 6c ) and Clusterin, or to participate in DNA repair, like Brca1, whereas the pro-apoptotic transcription factor Par-4 was upregulated (Table 2) . These results provide support to the higher sensitivity to cisplatin and etoposide of these cells. On the other hand, we found that mRNAs for cdk2 (confirmed also at the protein level, Figure 6c ) and cdk3, kinases required for G1/S progression, were downregulated whereas the mRNA for p16INK4, a cdk inhibitor, and cyclin D1 (see also Figure 4 ) were up-regulated. In addition, depletion of Sam68 led to a decrease in the mRNA levels of growth factors like EGF and IGF-1. The function of other genes altered in Sam68 depleted cells are less clearly implicated with cell proliferation and apoptosis. These data support the hypothesis that Sam68 is beneficial to proliferation and survival of prostate cancer cells.
Discussion
Post-transcriptional regulation of gene expression is often aberrant in cancer cells and changes in both alternative splicing and translational regulation of specific mRNAs have been reported (Ruggero and Sonenberg, 2005; Venables, 2006 in alternative splicing classify PCa phenotypes more accurately than changes in global transcription Zhang et al., 2006) . These observations indicate that factors influencing pre-mRNA processing could play a crucial role in determining the neoplastic progression of prostate cancer cells. Herein, we have investigated the role played in human PCas by Sam68, an RNA-binding protein involved in several aspects of mRNA processing (Lukong and Richard, 2003 Sam68 in prostate cancer R Busà et al of the cycle. However, they are not blocked and they reach confluence later than cells transfected with control scrambled siRNAs. Interestingly, the delay in cell cycle progression of LNCaP cells silenced for Sam68 affected accumulation in G2/M driven by nocodazole treatment. As unsynchronized LNCaP are prevalently in the G1 phase of the cycle, this result indicates that less LNCaP cells can reach the G2 phase in 16 h when Sam68 levels are reduced. On the other hand, it was previously shown that transient overexpression of Sam68 in nontransformed cells also caused a delay in G1 (Taylor et al., 2004) . Thus, it is possible that alterations in the cellular levels of Sam68 in either direction affect the normal G1 progression. Alternatively, Sam68 may play a different role in nontransformed and transformed cells. In line with the latter hypothesis, Src activity and tyrosine phosphorylation of Sam68, which affects its cellular function, are frequently increased in human PCas (Paronetto et al., 2004) . Similarly, phosphorylation of Sam68 on tyrosine 440 has been recently reported in specimens obtained from human breast cancer (Lukong et al., 2005) . As Srckinase inhibitors are known to interfere with prostate cancer cell proliferation and invasiveness (Nam et al., 2005) , it is possible that Sam68 is among the effectors of this pathway in human PCas. Depletion of Sam68 in LNCaP cells caused accumulation of cyclin D1. Interestingly, in androgen-sensitive prostate cancer cells accumulation of cyclin D1a (the most common isoform) interferes with the transcriptional activity of the androgen receptor thereby inhibiting proliferation (Burd et al., 2006) . Hence, our observation that cyclin D1 protein is upregulated in Sam68-depleted LNCaP may indicate that the decreased proliferative rate of these cells is due to downregulation of androgen receptor activity.
Perhaps more interesting is the observation that depletion of Sam68-sensitized LNCaP cells to apoptosis induced by DNA damaging agents. It has been previously reported that Sam68 and other splicing factors are re-localized in specific sub-nuclear compartments in response to heat shock of cells, suggesting a function for this protein in the cellular response to a stress (Denegri et al., 2001) . Indeed, depletion of Sam68 caused the downregulation of mRNAs encoding antiapoptotic factors (Bcl2L1 and Clusterin) or proteins involved in DNA repair (Brca1), whereas the proapoptotic transcription factor Par-4 is upregulated. Thus, our results suggest that maintaining high levels of Sam68 protein could be part of the adaptation mechanisms employed by cancer cells to withstand hostile environments.
The GSG domain of Sam68 is required for RNA binding, protein homodimerization and intracellular localization (Chen et al., 1999) . However, this domain lacks the motifs required for post-translational modification of Sam68 that affect its activity and localization (Lukong and Richard, 2003) . We reasoned that constitutive expression of this domain in cells may influence the activity of the endogenous Sam68 by forming heterodimers that are less susceptible to post-translational control. Indeed, we found that the GFP-Sam68 GSG efficiently dimerized with endogenous Sam68 in vivo and that LNCaP clones expressing GFP-Sam68 GSG strongly resemble cells depleted of Sam68 in terms of reduced proliferation and augmented sensitivity to apoptosis. These observations suggest that expression of the GSG domain alone interferes with Sam68 function in live cells and that this domain could be exploited as therapeutic target to limit the proliferation and survival of prostate cancer cells.
In conclusion, our finding that Sam68 is required for optimal proliferation and survival of prostate cancer cells may represent a first step to understand how these neoplastic cells alter their mRNA isoforms pattern during transformation.
Materials and methods
Human tissue samples
PCa were diagnosed by TRU-CUT biopsy, graded using the Gleason and the TNM grading systems (Table 1) and samples were obtained after informed consent from patients who underwent prostatectomy as previously described (Paronetto et al., 2004) .
Immunohistochemistry
Immunohistochemical staining was performed on formalinfixed tissue as described previously (Paronetto et al., 2006) with polyclonal rabbit anti-Sam68 (Santa Cruz Biotechnology, Santa Cruz, CA, USA, SC-133 1:800 dilution), rabbit anticyclin D1 (Dako, Carpinteria, CA, USA, 1:400 dilution) and rabbit anti-Ki67 (Dako, 1:400). Detection was accomplished using a biotin-streptavidin horseradish peroxides detection kit (Dako EnVision/HRP).
Extraction of RNA and proteins from cultured cells and primary tissue Total RNA was extracted by homogenization of samples in TRIzol reagent (Invitrogen, Life Technologies, Carlsbad, CA, USA). Real-time PCR was performed on cDNAs obtained with MMLV reverse transcriptase (Invitrogen). Applied Biosystems gene expression assays for 18S and GAPDH were used for relative expression according to manufaturer's instructions. Sam68 oligonucleotides used can be given upon request. For proteins extraction, LNCaP cells and tissue fragments were homogenized in lysis buffer (100 mM NaCl, 10 mM MgCl 2 , 30 mM Tris-HCl, pH 7.5, 1 mM dithiothreitol, protease inhibitor cocktail), supplemented with 1% Triton-X-100. Soluble extracts from 15 min centrifugation at 12 000 g at 41C, were used for Western blot.
Cell cultures and transfections
LNCaP cells were maintained in RPMI 1640 medium (BioWhittaker Cambrex Bioscience, Belgium) as described (Paronetto et al., 2004) . Cells at B50/60% confluency were transfected for 2 or 3 consecutive days with small interfering RNA (siRNAs) (MWG Biotech, Ebersberg, Germany) using Oligofectamine and Opti-MEM medium (Invitrogen). Sam68 siRNAs were: 5 0 -GGAUCUGCAUGUCUUCAUU-3 0 (si1Sam68) and 5 0 -CUGUCAGGAGCAAUUUCUA-3 0 (si2-Sam68). Scrambled siRNAs were: 5 0 -GUGCUCAAUUGGA UUCUCU-3 0 (si1 ctrl) and 5 0 -GGAGCUUCAUUGCUAUC AA-3 0 (si2 ctrl). For cell cycle block in different phases, LNCaP cells were treated with 100 mM L-mimosine (G1/S), or 2 mM thymidine (S) or 500 ng/ml nocodazole (G2/M) for 16 h, collected in PBS, incubated with 70% ethanol for 2 h, then treated with RNAseA (15 min at 371C) and 10 mg/ml propidium iodide (30 min at 371C) and analysed on a FACSCalibur Flow Cytometer (Becton Dickinson, San Jose`, CA, USA).
Immunoprecipitation assay
Nuclear and cytoplasmic extracts from LNCaP stable clones were prepared by resuspending cells in ipotonic buffer (10 mM Tris/HCl pH7.4, 10 mM NaCl, 2.5 mM MgCl 2 , 1 mM DTT, protease inhibitor cocktail (Sigma-Aldrich, St Louis, MO, USA). After incubation on ice for 7 min, samples were centrifuged at 700 g for 7 min. Pelleted nuclei were resuspended in ipotonic buffer supplemented with 90 mM NaCl and 0.5% Triton, sonicated and centrifuged (5000 g for 15 0 ) on 30% sucrose cushion. Nuclear extracts were pre-cleared on Protein A-sepharose beads (Sigma-Aldrich) and immunoprecipitated with 1 mg of anti-GFP for 3 h at 41C under constant shaking with Protein A-sepharose beads. Absorbed proteins were eluted and analysed by Western blot as described (Sette et al., 2002) .
LNCaP stable cell lines
The cDNA encoding the GSG domain of Sam68 was amplified by PCR using pCDNA3-GFP-Sam68 as template (Paronetto et al., 2003) and PFU polimerase (Roche), cloned in frame with GFP into pEGFP-C1 (CLONTECH, Mountain View, CA, USA) and sequenced. LNCaP cells were transfected with pEGFPC1 or pEGFP-GSG using Lipofectamine 2000 (Invitrogen) and selected by Geneticin (400 mg/ml, Invitrogen) 24 h after transfection. Geneticin-resistant foci were selected after 8-10 days, picked and expanded. pEGFP-GSG clones could be expanded with more difficulty because of their initial slow growth rate.
CD44 splicing assay PC3 prostate cancer cells were transfected with CD44 minigene (Matter et al., 2002) and constructs encoding GFP, GFPSam68 and mycGSG (Paronetto et al., 2006) . After 20 h cells were collected and RNA was isolated and reverse transcribed. PCR reactions were performed using the following primers: InsF 5 0 -CCTGGTGTGTGGGGAGCGT-3 0 and InsB 5 0 -CCA CCCAGCTCCAGTTGTGCCA-3 0 . Samples were separated on a 1.5% agarose gel and bands intensity was quantified.
GeArray prostate cancer biomarkers Total RNA was isolated using Rneasy Mini Kit (Qiagen Inc., Valencia, CA, USA) from transfected LNCaP cells and used as a template to generate biotin-16-UTP labelled cRNA probes by the True labelling kit (Superarray Inc., Bethesda, MD, USA). The cRNA probes were hybridised at 601C with the SuperArray Prostate cancer biomarkers membrane and signals were revealed using the SuperArray detection Kit. Data from three experiments were analysed by densitometry using the Scanalyze software (Eisen lab, Stanford University, CA, USA).
Additional Methods
Additional procedures can be found in the Supplementary materials.
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